Thymic stromal lymphopoietin improves protective immunity of the SARS-CoV-2 subunit vaccine by inducing dendritic cell-dependent germinal center response
Journal of Virology · 2025
DOI: 10.1128/jvi.02323-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, 2025. Verfasst von Hao Hu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, International Cancer Center, Shenzhen University Medical School, Shenzhen University, Shenzhen, China. Hauptthemen laut MEDLINE: Germinal Center, Cytokines, COVID-19 Vaccines, SARS-CoV-2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China (NSFC), Shenzhen Medical Research Fund, Guangdong Provincial Pearl River Talents Program.
Abstract (Originalsprache)
To effectively control viral pandemics, a multifaceted approach incorporating diverse vaccination strategies may be imperative. Our study demonstrates that both mucosal and non-mucosal immunization of mice with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) subunit vaccine enriched with thymic stromal lymphopoietin (TSLP) results in potent vaccine-specific systemic IgG and IgG1 antibody responses, but only mucosal immunization can induce robust mucosal IgA antibody and neutralizing antibody against SARS-CoV-2 wild-type, Alpha B.1.1.7, and Delta B.1.617.2 variant strains. We found that the immune-enhancing effect of TSLP relies on promoting dendritic cell (DC) migration and activation, which in turn enhances the germinal center (GC) responses. Furthermore, intranasal administration of the TSLP-adjuvanted vaccine protected against challenges from both SARS-CoV-2 wild-type and Delta B.1.617.2 strains. Our findings offer valuable insights into the importance of TSLP as a critical mucosal adjuvant in enhancing mucosal adaptive immunity by modulating DC-GC crosstalk, hence enhancing vaccination effectiveness. IMPORTANCE The current development and implementation of subunit vaccines in clinical practice encounter a number of challenges. The most significant difficulties are the scarcity of effective adjuvants and the fact that most vaccination programs rely on non-mucosal injections, which frequently fail to establish mucosal adaptive immunity and hence restrict the potential to protect against respiratory viral infections. Our research indicates that TSLP can effectively boost SARS-CoV-2 subunit vaccine-specific systemic and mucosal humoral immunity in mice after intranasal immunization, protecting them from SARS-CoV-2 wild-type and Delta variant infection. The mucosal adjuvant effects of TSLP depend on DC migration and activation, which boosts germinal center responses. Therefore, supplementation of mucosal subunit vaccines with TSLP should be considered in vaccine development, particularly when the vaccine is administered to children and the elderly. Our findings provide new evidence for the development of mucosal adjuvants for infectious diseases, potentially facilitating future vaccine development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, International Cancer Center, Shenzhen University Medical School, Shenzhen University, Shenzhen, China.
- Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, National Regional Key Technology Engineering Laboratory for Medical Ultrasound, School of Biomedical Engineering, Shenzhen University, Shenzhe…
- The First Affiliated Hospital of Guangzhou Medical University Guangzhou Medical University, Guangzhou, China.
- College of Pharmacy Shenzhen Technology University, Shenzhen, China.
Förderung
- National Natural Science Foundation of China (NSFC)
- Shenzhen Medical Research Fund
- Guangdong Provincial Pearl River Talents Program
- Research Team Cultivation Program of Shenzhen University
- Shenzhen Peacock Plan
Zitieren
APA
Hu, H., Zhang, Y., Zheng, H., Zhao, X., Ran, W., Liao, C., Lu, M., Zhou, J., Song, X., & Ye, L. (2025). Thymic stromal lymphopoietin improves protective immunity of the SARS-CoV-2 subunit vaccine by inducing dendritic cell-dependent germinal center response. Journal of Virology. https://doi.org/10.1128/jvi.02323-24
Vancouver
Hu H, Zhang Y, Zheng H, Zhao X, Ran W, Liao C, et al. Thymic stromal lymphopoietin improves protective immunity of the SARS-CoV-2 subunit vaccine by inducing dendritic cell-dependent germinal center response. Journal of Virology. 2025. doi:10.1128/jvi.02323-24
BibTeX
@article{Hu2025,
author = {Hu, Hao and Zhang, Ying and Zheng, Housheng and Zhao, Xiwen and Ran, Wei and Liao, Chenghui and Lu, Mingcheng and Zhou, Jian and Song, Xun and Ye, Liang},
title = {Thymic stromal lymphopoietin improves protective immunity of the SARS-CoV-2 subunit vaccine by inducing dendritic cell-dependent germinal center response},
journal = {Journal of Virology},
year = {2025},
doi = {10.1128/jvi.02323-24}
}
EUVIMED